Brian Lee Perkins

• Developed and implemented commercial strategies to enhance market presence and foster strategic partnerships in all segments to drive long-term growth and profitability in the United Kingdom • Collaborated with commercial leaders, functions and site leaders across all Thermo Fisher Scientific's 7 groups and 20+ divisions.

• Developed and implemented commercial strategies to enhance market presence and foster strategic partnerships in Biotech & BioPharma to drive long-term growth and profitability in the EMEA region. • Collaborated with the EMEA President, commercial leaders, functions, and country leaders across all Thermo Fisher Scientific's 7 groups and 20+ divisions.

🔹 2022: 276% 2022 H1 sales target European Cell & Gene Therapy Commercial SME

🔹 2021: 261% sales target. Labcorp Shining Star Achievement Award. 🔹 2020: 143% sales target. 2020 Covance Circle of Sales Excellence Award, Covance Sales Honor Roll.

🔹 2019: 149% sales target. 🔹 2018: 180% sales target. Covance Sales Honor Roll. 🔹 2017: 169% sales target. Covance Shining Star Achievement Award.

• Led development projects in clinical informatics, including Dementia Platform UK and SAIL Databank. • Engaged with industry partners, wrote grants, and advocated for policy change to support life sciences. • Achieved successful knowledge transfer, network building, and inward investment for the Health Informatics Group.

• Managed nonclinical and clinical development plans for lead siRNA candidates for allergic diseases at Allerna Therapeutics. • Sourced cGMP testing materials, designed GLP IND-/CTA-enabling studies, and evaluated technical and commercial feasibility for clinical trial designs. • Provided project management support to the executive team and offered guidance on regulatory and intellectual property landscape for antisense oligonucleotide technologies.

• Supported the development of the company's business plan and managed scientific research to cultivate the intellectual property portfolio. • Secured six-figure grant funding and co-invented 15 provisional patent applications progressing to 2 PCT applications with Nobel Laureate Prof Sir Martin Evans. • Activities resulted in spinouts Oncogeni Ltd (£5.5m acquisition by Roquefort Therapeutics PLC) and Cardiogeni PLC (£125m IPO)

• Managed nonclinical research operations and sales of IND-enabling studies at BioTox Sciences in the greater San Diego area. • Specialized in consulting on drug delivery and antisense oligonucleotides projects, as well a establishing bioanalytical capabilities such as qPCR. • Provided project management, Study Directorship, and sales support to client organizations.

• Managed protocol-driven studies on pharmacological, pharmacokinetic, and toxicological effects of compounds like pramlintide and exenatide. • Represented non-clinical development in cross-departmental project matrix teams and supported FDA regulatory submissions for Myalept (metreleptin). • Led scientific research staff and coordinated project management across internal Drug Delivery project.

• Designed and managed nonclinical protocol-driven studies for second generation antisense oligonucleotides (ASOs) at Ionis Pharmaceuticals. • Reported on off-site toxicity of non-CpG-containing 2' MOE-gapmers related to renal, hepatic, and inflammatory effects.

• Managed experiments and procedures in neuroscience, molecular biology, and cell biology alongside postdoctoral fellows within Mark Mayford's (Nobel Laureate Eric Kandel's Postdoc) Neuroscience Lab. • Developed a transgenic mouse for neuron visualization and manipulation, published in Science. • Screened an siRNA library revealing retinol saturase's role in cellular response to oxidative stress, published in Free Radical Biology and Medicine.

• Executed experiments and master batch records (MBRs) following cGMP/GLP guidelines for personalized therapeutic antibody-drug-conjugates (ADCs) against non-Hodgkin's lymphoma. • Optimized sequencing, production, and purification processes to ensure high-quality antibody development. • Collaborated with cross-functional teams to streamline operations and enhance efficiency in antibody production.